Enterprise Value

2.932B

Cash

201.2M

Avg Qtr Burn

-35.12M

Short % of Float

22.08%

Insider Ownership

0.54%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
IMCIVREE™ (Setmelanotide) Details
Rare genetic disease, Bardet-Biedl syndrome

Approved

Update

Approved

Quarterly sales

Approved

Quarterly sales

sNDA

Submission

NDA

FDA meeting

Phase 3

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 1

Data readout